H.C. Wainwright cuts AngioDynamics stock price target to $18
H.C. Wainwright reduced its price target for AngioDynamics (ANGO) to $18 from $19, maintaining a Buy rating. The company reported fiscal Q1 2027 net sales of $80.9M, up 6.9% YoY, but a net loss of $7.1M. Guidance for fiscal 2027 includes revenue of $336M-$341M and adjusted EBITDA of $13M-$16M. Canaccord Genuity reiterated its Buy rating with a $20 target, citing growth in key platforms. The stock fell 23% post-earnings.
How this was made
The 30-second read
Why it matters
The earnings miss and target reduction are likely to drive the stock lower in the near term.
Market read
The earnings release and analyst downgrade provide fresh, material information for traders of ANGO.
What to watch
Cash burn reduction and upcoming product launches (Auryon, NanoKnife) may support future upside.
Background
AngioDynamics reported Q1 2027 results with a 6.9% YoY revenue increase but a net loss of $7.1 M, and the analyst lowered the price target to $18.
Ticker impact
H.C. Wainwright lowered its price target on AngioDynamics to $18 after the company reported Q1 2027 earnings with a narrower loss and modest revenue beat.
likely pressure as the market prices in weaker guidance and the reduced price target.
Earnings showed a loss and guidance below prior expectations; the analyst's target cut reinforces a bearish outlook.
Market effects
MedTech sector may see modest pullback as a micro‑cap earnings miss highlights earnings volatility.
U.S. small‑cap biotech/medtech segment could face slight downside pressure.
Limited; primarily affects investors focused on niche medical device stocks.
Counterpoint
If the revenue beat signals a longer‑term growth trend, the stock could be undervalued despite the short‑term loss.
Key entities
- CompanyAngioDynamics
Medical device maker (NASDAQ: ANGO) reporting Q1 earnings.
- Research FirmH.C. Wainwright
Analyst house that cut the price target to $18.
